Mania Clinical Trial
Official title:
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode.
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo, as add-on to mood stabilizers and/or antipsychotic in the treatment of patients with bipolar disorder, in a manic episode.
An emerging body of evidence supports a role for dysfunctional purinergic related
neurotransmission in mood disorders [1, 2]. Adenosine agonists have been shown to have
properties similar to those of dopamine antagonists and there is a well characterized
antagonistic interaction between adenosine and dopamine receptors in the ventral striatum.
Increased adenosynergic transmission has been demonstrated to reduce the affinity of
dopamine agonists for dopamine receptors. It has been theorized that adenosine may exert
some of its antipsychotic effects through modulation of glutamatergic transmission.
Two double-blind, randomized, add-on, placebo-controlled trials comparing allopurinol and
placebo in acute mania have showed statistically significant greater improvements in YMRS
scores in the allopurinol vs. placebo groups. These empiric data, together with the
theoretical and basic science background cited, provide the impetus for this proposed study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT00534222 -
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
|
N/A | |
Completed |
NCT00140179 -
Valnoctamide in Mania
|
Phase 3 | |
Completed |
NCT01237379 -
Peroxisomal Defects and Familial Risk for Bipolar Disorder
|
N/A | |
Completed |
NCT01315028 -
Bipolar Intervention Study: Cognitive Interpersonal Therapy
|
N/A | |
Completed |
NCT00254488 -
Treatment of Bipolar Mania in Older Adults
|
Phase 4 | |
Completed |
NCT00560079 -
Efficacy of Allopurinol and Dypiridamole in Acute Mania
|
Phase 4 | |
Completed |
NCT00518947 -
Pharmacotherapy of Treatment-Resistant Mania
|
Phase 3 | |
Recruiting |
NCT05444907 -
Deep Brain Stimulation-Induced Mania in Parkinson's Disease
|
||
Enrolling by invitation |
NCT02360267 -
Pediatric Bipolar Registry
|
||
Completed |
NCT00521365 -
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
|
Phase 4 | |
Completed |
NCT01191918 -
The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania
|
Phase 4 | |
Completed |
NCT01541605 -
Methylphenidate for the Treatment of Acute Mania
|
Phase 3 | |
Completed |
NCT00893581 -
Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
|
N/A | |
Completed |
NCT00208195 -
Depakote ER Therapy for Mania Comorbid With Substance Abuse
|
Phase 4 | |
Completed |
NCT00181922 -
Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder
|
Phase 4 | |
Completed |
NCT00181935 -
Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder
|
Phase 4 | |
Active, not recruiting |
NCT05703711 -
Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa
|
N/A | |
Completed |
NCT00917501 -
Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania
|
Phase 2 | |
Completed |
NCT00334347 -
A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR
|
Phase 4 |